Nelfinavir, A Lead HIV Protease Inhibitor, Is a Broad-Spectrum, Anticancer Agent that Induces Endoplasmic Reticulum Stress, Autophagy, and Apoptosis In vitro and In vivo

  title={Nelfinavir, A Lead HIV Protease Inhibitor, Is a Broad-Spectrum, Anticancer Agent that Induces Endoplasmic Reticulum Stress, Autophagy, and Apoptosis In vitro and In vivo},
  author={Joell J. Gills and Jaclyn LoPiccolo and Junji Tsurutani and Robert H. Shoemaker and Carolyn J. M. Best and Mones S. Abu-Asab and Jennifer P. Borojerdi and Noel Andrew Warfel and Erin R. Gardner and Matthew L Danish and Mary Christine Hollander and Shigeru Kawabata and Maria G. Tsokos and William Douglas Figg and Patricia S. Steeg and Phillip A. Dennis},
  journal={Clinical Cancer Research},
  pages={5183 - 5194}
Purpose: The development of new cancer drugs is slow and costly. HIV protease inhibitors are Food and Drug Administration approved for HIV patients. Because these drugs cause toxicities that can be associated with inhibition of Akt, an emerging target in cancer, we assessed the potential of HIV protease inhibitors as anticancer agents. Experimental Design: HIV protease inhibitors were screened in vitro using assays that measure cellular proliferation, apoptotic and nonapoptotic cell death… 

Figures from this paper

Nelfinavir, a new anti-cancer drug with pleiotropic effects and many paths to autophagy

In vivo, nelfinavir inhibits tumor growth and upregulates markers of ER stress, autophagy and apoptosis, and is currently being tested in cancer patients in Phase I clinical trials where biomarkers will be assessed.

Nelfinavir induces TRAIL receptor upregulation in ovarian cancer cells.

Two Novel Precursors of the HIV-1 Protease Inhibitor Darunavir Target the UPR/Proteasome System in Human Hepatocellular Carcinoma Cell Line HepG2

These findings demonstrate that two compounds, R DD-19 and RDD-142, have pleiotropic effects and that they may represent promising anticancer candidates.

Study of anti-tumoral activity of HIV-Protease Inhibitor nelfinavir and identification of new nelfinavir-derivative compounds

The anti-cancer effectiveness of nelfinavir has motivated its use as lead compound in this study to design novel anti-tumoral compounds and primary screening has led to the identification of novel nELFinavir-derivative (4n) with a high anti- cancer efficacy (IC50 50nM), that is a promising molecule to further evaluate for cancer therapy.

Insights into the broad cellular effects of nelfinavir and the HIV protease inhibitors supporting their role in cancer treatment and prevention

Nelfinavir and other protease inhibitors are well tolerated, oral drugs that have promising antitumor properties, and may prove to play an important role in the prevention and treatment of several cancers.

The mitochondria-independent cytotoxic effect of nelfinavir on leukemia cells can be enhanced by sorafenib-mediated mcl-1 downregulation and mitochondrial membrane destabilization

The ability of nelfinavir to induce apoptosis in leukemia cells as a single agent in a mitochondria-independent manner might suggest it could be used as a second or third line of treatment for leukemia patients for whom standard mitochondrial-directed treatment strategies have failed.

Nelfinavir, an HIV-1 Protease Inhibitor, Induces Oxidative Stress–Mediated, Caspase-Independent Apoptosis in Leishmania Amastigotes

It is suggested that nelfinavir induces oxidative stress in Leishmania amastigotes, culminating in caspase-independent apoptosis, in which DNA is degraded by endonuclease G.

CH05‐10, a novel indinavir analog, is a broad‐spectrum antitumor agent that induces cell cycle arrest, apoptosis, endoplasmic reticulum stress and autophagy

It is demonstrated that CH05‐10, a novel indinavir analog, is a potent anticancer agent with pleiotropic effects.



HIV protease inhibitor nelfinavir inhibits growth of human melanoma cells by induction of cell cycle arrest.

The results suggest that nelfinavir is a promising candidate chemotherapeutic agent for advanced melanoma, for which novel and effective therapies are urgently needed.

The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cells.

It is concluded that saquinavir inhibits proteasome activity in mammalian cells as well as acting on the HIV-I protease, which might become a new class of cytotoxic drugs, alone or in combination with radiation or chemotherapy.

HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both in vitro and in vivo.

In tumor cells with mutations in epidermal growth factor receptor, doses of amprenavir or nelfinavir comparable with the therapeutic levels achieved in HIV patients were sufficient to down-regulate phosphorylation of Akt in SQ20B and T24 xenografts, and overexpression of active PI3K in cells without activated Akt resulted in radiation resistance that could be inhibited with HPIs.

HIV-1 protease inhibitor induces growth arrest and apoptosis of human multiple myeloma cells via inactivation of signal transducer and activator of transcription 3 and extracellular signal-regulated kinase 1/2.

Protease inhibitors might be useful for treatment of individuals with multiple myeloma and inhibit production of vascular endothelial growth factor one of the targets of STAT 3, in U266 and RPMI8226 cells as measured by ELISA.

HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma

Systemic administration of the PIs indinavir or saquinavir to nude mice blocks the development and induces regression of angioproliferative KS-like lesions promoted by primary human KS cells, basic fibroblast growth factor, or bFGF and vascular endothelial growth factor combined.

A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection.

Study of viral genotype and phenotype after virus rebound revealed that the initial active site mutation allowing for nelfinavir resistance is mediated by a unique amino acid substitution in the HIV-1 protease D30N, which does not confer in vitro phenotypic cross-resistance to the currently available protease inhibitors.

HIV‐1 protease inhibitor induces growth arrest and apoptosis of human prostate cancer LNCaP cells in vitro and in vivo in conjunction with blockade of androgen receptor STAT3 and AKT signaling

Taken together, NFV inhibited the proliferation of prostate cancer cells in conjunction with blockade of signaling by AR, STAT3, and AKT, suggesting that this family of compounds might be useful for the treatment of individuals with prostate cancer.

Nelfinavir mesylate

Initial trials and clinical experience indicate that nelfinavir is equipotent to other potent protease inhibitors (PIs), and it has become the most frequently prescribed first line PI.

Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis.

It is established that bortezomib sensitizes pancreatic cancer cells to ER stress-induced apoptosis and show that bortsomib strongly enhances the anticancer activity of cisplatin.

Nelfinavir Mesylate: A Protease Inhibitor

The choice of antiretroviral (ARV) regimens should be made based on the risk of disease progression as indicated by HIV RNA concentrations and CD4+ cell counts, patients' previous ARV experiences and responses, concomitant drug therapy, compliance history, underlying disease states, and adverse reaction history.